A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (TARGET-D 203)
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Verastem Call Center
- 电话号码:7812924204
- 邮箱:VS-7375-203TrialSupport@verastem.com
研究联系人备份
- 姓名:Bina Tejura, MD
- 邮箱:VS-7375-203Medical@verastem.com
学习地点
-
-
New South Wales
-
Macquarie Park、New South Wales、澳大利亚、2109
- 招聘中
- Macquarie University Hospital
-
接触:
- Sam Ly
- 电话号码:+612 9812 3538
- 邮箱:sam.ly@mq.edu.au
-
接触:
- Jignasa Mahida
- 电话号码:+61 466 476 498
- 邮箱:Jignasa.mahida@mq.edu.au
-
首席研究员:
- Andrew Parsonson, MBBS MMed (Clin Epi) FRACP
-
Waratah、New South Wales、澳大利亚、2298
- 招聘中
- Calvary Mater Newcastle
-
首席研究员:
- Girish Mallesara, MBBS, MD, DM, FRACP
-
接触:
- Kerrie Cornall
- 电话号码:02 4014 3290
- 邮箱:Kerrie.Cornall@health.nsw.gov.au
-
-
Queensland
-
Hyde Park、Queensland、澳大利亚、4812
- 招聘中
- Icon Cancer Centre Townsville
-
接触:
- Peyman Halvaeikhanekahdani
- 电话号码:61747957100
- 邮箱:peyman.halvaeikhanekahdani@icon.team
-
首席研究员:
- Abhishek Joshi, MBBS, MD, DM, FRACP
-
South Brisbane、Queensland、澳大利亚、4101
- 招聘中
- Icon Cancer Centre South Brisbane
-
首席研究员:
- Jermaine Coward, MBBS, MRCP (UK), FRACP, PhD
-
接触:
- Apryl Chelin
- 电话号码:07 3737 4700
- 邮箱:Apryl.chelin@icon.team
-
-
South Australia
-
Kurralta Park、South Australia、澳大利亚、5037
- 招聘中
- Icon Cancer Centre Adelaide
-
首席研究员:
- Carolyn Bampton, MBBS, FRACP
-
接触:
- Icon Cancer Centre Adelaide/Kurralta Park
- 电话号码:08 8474 0220
- 邮箱:EthicsCoordinator@icon.team
-
-
Tasmania
-
Hobart、Tasmania、澳大利亚、7000
- 招聘中
- Icon Cancer Centre Hobart
-
接触:
- Icon Cancer Centre Hobart
- 电话号码:03 6240 2600
- 邮箱:hobart.research@icon.team
-
首席研究员:
- Louise Nott, BMedSci, MBBS(Hons), FRACP
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3004
- 招聘中
- Alfred Hospital
-
接触:
- Ben Markman, MBBS (Hons), FRACP
- 电话号码:390763129
- 邮箱:ben.markman@monash.edu
-
接触:
- Kate Sinn
- 电话号码:390760569
- 邮箱:K.Sinn@alfred.org.au
-
首席研究员:
- Ben Markman, MBBS (Hons), FRACP
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85258
- 招聘中
- HonorHealth
-
首席研究员:
- Sunil Sharma, MD
-
接触:
- Sunil Sharma, MD
- 电话号码:480-323-1350
- 邮箱:ssharma@honorhealth.com
-
-
California
-
Los Angeles、California、美国、90048
- 招聘中
- Cedars-Sinai Medical Center
-
接触:
- Cedars-Sinai Trial Information
- 电话号码:1-800-233-2771
- 邮箱:GroupCancerTrialInformation@cshs.org
-
首席研究员:
- Jun Gong, MD
-
Los Angeles、California、美国、90025
- 招聘中
- START Los Angeles
-
接触:
- START Hope Team
- 电话号码:424-465-1820
- 邮箱:hopeteam@startresearch.com
-
首席研究员:
- Navid Hafez, M.D., MPH
-
Los Angeles、California、美国、90067
- 招聘中
- Valkyrie Clinical Trials (contact for more locations)
-
首席研究员:
- David Berz, MD, PhD, MPH
-
接触:
- Trenis Palmer, PhD
- 电话号码:912-398-3205
- 邮箱:trenis.palmer@vctcare.com
-
-
Florida
-
Coral Springs、Florida、美国、33065
- 招聘中
- BRCR - Coral Springs
-
首席研究员:
- Sumit Sawhney, MD
-
接触:
- Sumit Sawhney, MD
- 电话号码:561-447-0614
- 邮箱:ssawhney.md@brcrglobal.com
-
Tamarac、Florida、美国、33321
- 招聘中
- BRCR - Tamarac
-
首席研究员:
- Andrew Schneider, MD
-
接触:
- Diana Casas
- 电话号码:561-447-0614
- 邮箱:dianac@brcrglobal.com
-
Tampa、Florida、美国、33612
- 招聘中
- Moffitt Cancer Center
-
首席研究员:
- Tiago Biachi de Castria, MD, PhD
-
接触:
- Cheyenne Schneider
- 电话号码:813-745-3691
- 邮箱:Cheyenne.Schneider@moffitt.org
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- 招聘中
- Indiana University, Simon Comprehensive Cancer Center
-
接触:
- Yvonne LaFary
- 电话号码:317-278-5613
- 邮箱:ylafary@iu.edu
-
首席研究员:
- Anita Turk, M.D.
-
-
Michigan
-
Grand Rapids、Michigan、美国、49546
- 招聘中
- START Midwest
-
接触:
- START Hope Team
- 电话号码:616-954-5554
- 邮箱:hopeteam@startresearch.com
-
首席研究员:
- Sreenivasa R Chandana, M.D., Ph.D.
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University
-
首席研究员:
- Kian-Huat Lim, M.D., Ph.D.
-
接触:
- Caroline Bumb
- 电话号码:314-747-4000
- 邮箱:cbumb@wustl.edu
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- 招聘中
- START New Jersey
-
接触:
- START Hope Team
- 电话号码:732-426-4750
- 邮箱:hopeteam@startresearch.com
-
首席研究员:
- Bruno S Fang, M.D.
-
-
New York
-
New York、New York、美国、10016
- 招聘中
- Perlmutter Cancer Center at NYU Langone Health (contact for more locations)
-
接触:
- Rafael Winograd, MD, PhD
- 电话号码:646-501-7802
- 邮箱:CancerTrials@nyulangone.org
-
首席研究员:
- Rafael Winograd, MD, PhD
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- 招聘中
- University of North Carolina
-
接触:
- Catherine Griffin
- 电话号码:919-966-4432
- 邮箱:catherine_griffin@med.unc.edu
-
首席研究员:
- Michael Iglesia, MD, PhD
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 招聘中
- Case Western, University Hospitals Cleveland Medical Center
-
首席研究员:
- Amit Mahipal, MD
-
接触:
- Amit Mahipal, MD
- 电话号码:(216)844-6031
- 邮箱:Amit.Mahipal@UHhospitals.org
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Sarah Cannon Research Institute Oncology Partners
-
首席研究员:
- Meredith Pelster, MD
-
接触:
- ASK SARAH
- 电话号码:877-691-7274
- 邮箱:askSARAH@scresearch.net
-
-
Texas
-
Fort Worth、Texas、美国、76104
- 招聘中
- START Dallas Fort Worth
-
接触:
- START Hope Team
- 电话号码:682-350-3010
- 邮箱:hopeteam@startresearch.com
-
首席研究员:
- Salwan Al Mutar, M.D., M.Sc.
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas MD Anderson Cancer Center
-
首席研究员:
- Christine Parseghian, MD
-
接触:
- MD Anderson Cancer Center, GI Medical Oncology Dept
- 电话号码:855-982-0789
- 邮箱:GIClinicalTrials@mdanderson.org
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- Huntsman Cancer Institute - University of Utah
-
首席研究员:
- Christopher Nevala-Plagemann, MD
-
接触:
- Susan Sharry
- 电话号码:801-585-3453
- 邮箱:susan.sharry@hci.utah.edu
-
West Valley City、Utah、美国、84119
- 招聘中
- START Mountain Region
-
接触:
- START Hope Team
- 电话号码:801-907-4750
- 邮箱:hopeteam@startresearch.com
-
首席研究员:
- José M Pacheco, M.D.
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 招聘中
- UVA Comprehensive Cancer Center
-
首席研究员:
- Matthew Reilley, MD
-
接触:
- Clinical Trials Navigator
- 电话号码:434-982-0539
- 邮箱:UVACANCERTRIALS@uvahealth.org
-
Fairfax、Virginia、美国、22031
- 招聘中
- Virginia Cancer Specialists
-
接触:
- VCS Research Referrals
- 电话号码:703-636-1473
- 邮箱:vcsresearchreferrals@usoncology.com
-
-
Washington
-
Seattle、Washington、美国、98101
- 招聘中
- Virginia Mason Medical Center
-
接触:
- Cancer Research Team
- 电话号码:206-287-6270
- 邮箱:crp@benaroyaresearch.org
-
首席研究员:
- Jessica Lee, DO
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- 招聘中
- University of Wisconsin
-
首席研究员:
- Dustin Deming, MD
-
接触:
- UW Cancer Connect
- 电话号码:800-622-8922
- 邮箱:cancerconnect@uwhealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Histopathology confirmed metastatic CRC
-
Measurable disease per RECIST 1.1
-
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
-
ECOG PS=0 or 1
2L+ patients:
-
Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma
-
Have documented disease progression during or following their most recent prior line of therapy
-
Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.
1L patients:
-
Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.
Exclusion Criteria:
- Have any other documented co-existing common RAS mutation(s)
- Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
- Major surgery within 4 weeks of first treatment dose
- Radiation therapy (RT) within 1 week of first treatment dose
- Receipt of prior direct RAS inhibitor
- Receipt of more than 1 investigational therapy
- Untreated or symptomatic CNS metastasis
- Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
- Receipt of PPI or H2 blocker within 5 days
- Inability to swallow oral medication
- Other protocol-defined inclusion/exclusion criteria may apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:VS-7375 with chosen regimen in 2L+ CRC
|
Taken by mouth Intravenous infusion Intravenous infusion |
|
实验性的:VS-7375 + cetuximab and mFOLFOX in 1L CRC
|
Intravenous infusion |
|
实验性的:VS-7375 Monotherapy or Preferred Combination in 2L+ CRC
Participants randomized to a treatment in 2:1 ratio |
Taken by mouth Intravenous infusion Intravenous infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only
大体时间:6 months
|
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR) |
6 months
|
|
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC
大体时间:6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
|
To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC
大体时间:6 months
|
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations |
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax
大体时间:20 weeks
|
Maximum concentration (Cmax) |
20 weeks
|
|
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC
大体时间:20 weeks
|
Area under plasma Concentration (AUC) 0 to t |
20 weeks
|
|
To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type
大体时间:Up to 2.5 years
|
CA19-9, CEA, CA-125 |
Up to 2.5 years
|
|
Time to next therapy
大体时间:24 months
|
To assess the interval between initiation of study treatment and initiation of subsequent treatment |
24 months
|
|
Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments
大体时间:24 months
|
To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC |
24 months
|
|
To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)
大体时间:24 months
|
The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients |
24 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Imaging of tumor metabolism changes in 2L monotherapy patients
大体时间:24 months
|
To assess tumor metabolism dynamics on FDG-PET/CT |
24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.